Advertisement

Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population

  • Regina JuanbeltzEmail author
  • Jesús Castilla
  • Iván Martínez-Baz
  • Aisling O’Leary
  • Maite Sarobe
  • Ramón San Miguel
Article

Abstract

Purpose

To compare health-related quality of life (HRQoL) between hepatitis C patients who achieve sustained virological response (SVR) to direct-acting antivirals and a sex- and age-paired sample of the general population.

Methods

HRQoL was evaluated in patients recruited in Navarre, Spain, from May 2016 to April 2017 at baseline and after SVR, using the EQ-5D-5L questionnaire. Both results were compared to those of general population of the same sex and age obtained from the 2011/12 National Health Survey in Spain. Observed/expected (O/E) ratios for health dimensions and differences between O-E in EQ-5D utility and visual analogical scale (VAS) scores were calculated.

Results

206 patients were studied. Before treatment, patients had more problems than the general population in every domain of EQ-5D-5L, except in self-care dimension (O/E = 1.1). After SVR, patients continued having more limitation, especially for usual activities (O/E = 3.1), anxiety/depression (O/E = 2.8) and EQ-5D utility (− 0.086, p < 0.001); however, differences in VAS score between patients and general population disappeared (74.8 vs 76.5, p = 0.210). F0–F1 patients with SVR had minor differences with the general population in EQ-5D-5L dimensions, utility and VAS score. Although cirrhotic patients also reduced that difference, they still had worse HRQoL, especially in usual activities, self-care, EQ-5D utility (− 0.152, p < 0.001) and VAS score (− 8.5, p = 0.005).

Conclusions

HRQoL of chronic hepatitis C patients remains lower than that of the general population despite viral clearance, with primary problems in usual activities and anxiety/depression. Knowledge of these on-going problems despite cure serves to guide healthcare interventions and patient’s follow-up.

Keywords

Health-related quality of life Quality of life Hepatitis C Direct-acting antiviral EQ-5D Population norms 

Notes

Acknowledgements

This work is part of the EIPT-VHC project, which was supported by the Spanish Ministry of Health and by the Carlos III Health Institute in the context of the “Strategic Plan for Tackling Hepatitis C in the Spanish National Health System”. Regina Juanbeltz and Jesús Castilla have received funding from the Carlos III Institute of Health with the European Regional Development Fund (CM17/00095, INT17/00066). These institutions did not have any role in the research and writing of this manuscript.

Funding

This work is part of the EIPT-VHC project, which was supported by the Spanish Ministry of Health and by the Carlos III Health Institute in the context of the “Strategic Plan for Tackling Hepatitis C in the Spanish National Health System”. These institutions did not have any role in the research and writing of this manuscript.

Compliance with ethical standards

Conflict of interest

RJ and JC have received research grants from Carlos III Institute of Health with the European Regional Development Fund, during the conduct of the study (CM17/00095, INT17/00066). IMB, AO, MS and RSM declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

11136_2019_2111_MOESM1_ESM.xls (3.3 mb)
Supplementary material 1 (XLS 3424 KB)

References

  1. 1.
    Lingala, S., & Ghany, M. G. (2015). Natural history of hepatitis C. Gastroenterology clinics of North America, 44(4), 717–734.CrossRefGoogle Scholar
  2. 2.
    Degasperi, E., Aghemo, A., & Colombo, M. (2017). Treatment of extrahepatic manifestations of hepatitis C virus. Clinics in Liver Disease, 21(3), 631–643.CrossRefGoogle Scholar
  3. 3.
    Juanbeltz, R., Zozaya, J. M., Reparaz, J., Castilla, J., Sarobe, M. T., Uriz Otano, J. I., et al. (2017). Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C. Anales del Sistema Sanitario de Navarra, 40(1), 57–66.Google Scholar
  4. 4.
    Juanbeltz, R., Goñi Esarte, S., Uriz-Otano, J. I., Martinez Echeverria, A., Elizalde, I., Zozaya, J. M., et al. (2017). Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. Postgraduate Medicine, 129(4), 476–483.CrossRefGoogle Scholar
  5. 5.
    Kouris, G., Hydery, T., Greenwood, B. C., Lavitas, P., Price, M., Clements, K., et al. (2018). Effectiveness of Ledipasvir/Sofosbuvir and predictors of treatment failure in members with hepatitis C genotype 1 infection: A retrospective cohort study in a medicaid population. Journal of Managed Care and Specialty Pharmacy, 24(7), 591–597.CrossRefGoogle Scholar
  6. 6.
    Honer Zu Siederdissen, C., Buggisch, P., Boker, K., Schott, E., Klinker, H., Pathil, A., et al. (2018). Treatment of hepatitis C genotype 1 infection in Germany: Effectiveness and safety of antiviral treatment in a real-world setting. United European Gastroenterology Journal, 6(2), 213–224.CrossRefGoogle Scholar
  7. 7.
    Hezode, C. (2018). Treatment of hepatitis C: Results in real life. Liver International, 38(Suppl 1), 21–27.CrossRefGoogle Scholar
  8. 8.
    San Miguel, R., Gimeno-Ballester, V., Blazquez, A., & Mar, J. (2015). Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut, 64(8), 1277–1288.CrossRefGoogle Scholar
  9. 9.
    Jakobsen, J. C., Nielsen, E. E., Koretz, R. L., & Gluud, C. (2018). Do direct acting antivirals cure chronic hepatitis C? British Medical Journal, 361, k1382.CrossRefGoogle Scholar
  10. 10.
    Foster, G. R., Goldin, R. D., & Thomas, H. C. (1998). Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology, 27(1), 209–212.CrossRefGoogle Scholar
  11. 11.
    Bjornsson, E., Verbaan, H., Oksanen, A., Fryden, A., Johansson, J., Friberg, S., et al. (2009). Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scandinavian Journal of Gastroenterology, 44(7), 878–887.CrossRefGoogle Scholar
  12. 12.
    Cordoba, J., Flavia, M., Jacas, C., Sauleda, S., Esteban, J. I., Vargas, V., et al. (2003). Quality of life and cognitive function in hepatitis C at different stages of liver disease. Journal of Hepatology, 39(2), 231–238.CrossRefGoogle Scholar
  13. 13.
    Dusheiko, G. (2017). The impact of antiviral therapy for hepatitis C on the quality of life: A perspective. Liver International, 37(1), 7–12.CrossRefGoogle Scholar
  14. 14.
    Juanbeltz, R., Martínez-Baz, I., San Miguel, R., Goñi-Esarte, S., Cabasés, J. M., & Castilla, J. (2018). Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLoS ONE, 13(10), e0205277.CrossRefGoogle Scholar
  15. 15.
    San Miguel, R., del Villar, V., Perez, C., de Frutos, M., Mar, J., & Coma, M. J. (2010). Role of health-related quality of life measurements in the design of drug clinical trials. Farmacia Hospitalaria, 34(1), 16–22.CrossRefGoogle Scholar
  16. 16.
    Miguel, R. S., Lopez-Gonzalez, A. M., Sanchez-Iriso, E., Mar, J., & Cabases, J. M. (2008). Measuring health-related quality of life in drug clinical trials: Is it given due importance? Pharmacy World and Science, 30(2), 154–160.CrossRefGoogle Scholar
  17. 17.
    European Association for the Study of the Liver. (2018). EASL Recommendations on treatment of hepatitis C 2018. J Hepatol, 69(2), 461–511.CrossRefGoogle Scholar
  18. 18.
    de Sanidad, M., Servicios Sociales e Igualdad. Encuesta Nacional de Salud de España. (2016). Retrieved May 22, 2018, from https://www.mscbs.gob.es/estadEstudios/estadisticas/encuestaNacional/home.htm.
  19. 19.
    Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., et al. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. Quality of Life Research, 22(7), 1717–1727.CrossRefGoogle Scholar
  20. 20.
    Devlin, N. J., Parkin, D., & Browne, J. (2010). Patient-reported outcome measures in the NHS: New methods for analysing and reporting EQ-5D data. Health Economics, 19(8), 886–905.CrossRefGoogle Scholar
  21. 21.
  22. 22.
    Bedossa, P., & Poynard, T. (1996). An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 24(2), 289–293.CrossRefGoogle Scholar
  23. 23.
    Rothman, K., & Boice, J. D. (1979). Epidemiologic analysis with a programmable calculator. Washington, DC: U.S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health.Google Scholar
  24. 24.
    Dean, A. G., Sullivan, K. M., Soe, M. M.. OpenEpi: Open source epidemiologic statistics for public health. (2013). Retrieved December 31, 2018, from https://www.OpenEpi.com.
  25. 25.
    Manuel, D. G., Schultz, S. E., & Kopec, J. A. (2002). Measuring the health burden of chronic disease and injury using health adjusted life expectancy and the health utilities index. J Epidemiol Community Health, 56(11), 843–850.CrossRefGoogle Scholar
  26. 26.
    Fotos, N. V., Elefsiniotis, I., Patelarou, A., Giakoumidakis, K., Patelarou, E., Kouros, A., et al. (2018). Psychological disorders and quality of life among patients with chronic viral hepatitis: A single-center cross-sectional study with pair-matched healthy controls. Gastroenterology Nursing, 41(3), 206–218.CrossRefGoogle Scholar
  27. 27.
    Hussain, K. B., Fontana, R. J., Moyer, C. A., Su, G. L., Sneed-Pee, N., & Lok, A. S. (2001). Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. American Journal of Gastroenterology, 96(9), 2737–2744.CrossRefGoogle Scholar
  28. 28.
    Younossi, Z., Kallman, J., & Kincaid, J. (2007). The effects of HCV infection and management on health-related quality of life. Hepatology, 45(3), 806–816.CrossRefGoogle Scholar
  29. 29.
    de Sanidad, M. Servicios Sociales e Igualdad. (2017). Plan estratégico para el abordaje de la hepatitis C en el Sistema Nacional de Salud. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad. Retrieved June 25, 2018, from https://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/home.htm.
  30. 30.
    Younossi, Z. M., Stepanova, M., Feld, J., Zeuzem, S., Sulkowski, M., Foster, G. R., et al. (2017). Sofosbuvir and velpatasvir combination improves patient-reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis. Clinical Gastroenterology and Hepatology, 15(3), 421–430.e6.CrossRefGoogle Scholar
  31. 31.
    Marcellin, F., Roux, P., Protopopescu, C., Duracinsky, M., Spire, B., & Carrieri, M. P. (2017). Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Review of Gastroenterol and Hepatology, 11(3), 259–268.Google Scholar
  32. 32.
    Younossi, Z. M., Stepanova, M., Henry, L., Nader, F., & Hunt, S. (2016). An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. The American Journal of Gastroenterology, 111(6), 808–816.CrossRefGoogle Scholar
  33. 33.
    Ragusa, R., Bertino, G., Bruno, A., Frazzetto, E., Cicciu, F., Giorgianni, G., et al. (2018). Evaluation of health status in patients with hepatitis c treated with and without interferon. Health and Quality of Life Outcomes, 16(1), 17.CrossRefGoogle Scholar
  34. 34.
    Thein, H. H., Krahn, M., Kaldor, J. M., & Dore, G. J. (2005). Estimation of utilities for chronic hepatitis C from SF-36 scores. The American Journal of Gastroenterology, 100(3), 643–651.CrossRefGoogle Scholar
  35. 35.
    Chong, C. A., Gulamhussein, A., Heathcote, E. J., Lilly, L., Sherman, M., Naglie, G., et al. (2003). Health-state utilities and quality of life in hepatitis C patients. The American Journal of Gastroenterology, 98(3), 630–638.CrossRefGoogle Scholar
  36. 36.
    Van Rooijen, E. M., Hotho, D., Agthoven, M., Van Der Kolk, A., Hansen, B. E., Knegt, R., & Uyl-De Groot, C. A. (2011). The cost and quality of life of hepatitis C in the Netherlands. Value in Health, 14, A394. [Conference abstract].CrossRefGoogle Scholar
  37. 37.
    Buchanan-Hughes, A. M., Buti, M., Hanman, K., Langford, B., Wright, M., & Eddowes, L. A. (2018). Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: A systematic literature review and meta-analysis. Quality of Life Research.  https://doi.org/10.1007/s11136-018-1992-3.Google Scholar
  38. 38.
    Lens, S., Alvarado-Tapias, E., Mariño, Z., Londoño, M. C., Llop, E., Martinez, J., et al. (2017). Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology, 153(5), 1273–1283.e1.CrossRefGoogle Scholar
  39. 39.
    D’Ambrosio, R., Aghemo, A., Rumi, M. G., Ronchi, G., Donato, M. F., Paradis, V., et al. (2012). A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology, 56(2), 532–543.CrossRefGoogle Scholar
  40. 40.
    Badia, X., Monserrat, S., Roset, M., & Herdman, M. (1999). Feasibility, validity and test-retest reliability of scaling methods for health states: the visual analogue scale and the time trade-off. Quality of Life Research, 8(4), 303–310.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Hospital PharmacyComplejo Hospitalario de Navarra-IdiSNAPamplonaSpain
  2. 2.Instituto de Salud Pública de Navarra-IdiSNAPamplonaSpain
  3. 3.CIBER Epidemiología y Salud Pública (CIBERESP)PamplonaSpain
  4. 4.National Centre for Pharmacoeconomics, St Jame’s HospitalDublinIreland
  5. 5.School of PharmacyRoyal College of Surgeons in IrelandDublinIreland

Personalised recommendations